# DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy

> **NCT07024693** · PHASE2 · RECRUITING · sponsor: **Design Therapeutics, Inc.** · enrollment: 28 (estimated)

## Conditions studied

- Fuchs Endothelial Corneal Dystrophy
- Fuchs

## Interventions

- **DRUG:** DT-168

## Key facts

- **NCT ID:** NCT07024693
- **Lead sponsor:** Design Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-30
- **Primary completion:** 2026-09
- **Final completion:** 2026-12
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2025-12-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07024693

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07024693, "DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07024693. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*